|1.||Lipton, Allan: 12 articles (09/2015 - 02/2002)|
|2.||Garnero, P: 12 articles (03/2009 - 02/2000)|
|3.||Delmas, P D: 10 articles (10/2003 - 01/2000)|
|4.||Coleman, Robert E: 8 articles (03/2010 - 05/2002)|
|5.||Fizazi, Karim: 7 articles (09/2015 - 04/2009)|
|6.||Saad, Fred: 7 articles (09/2015 - 01/2005)|
|7.||Eastell, Richard: 7 articles (12/2014 - 01/2003)|
|8.||Terpos, Evangelos: 7 articles (01/2014 - 09/2004)|
|9.||Christgau, S: 7 articles (03/2009 - 05/2001)|
|10.||Inaba, Masaaki: 6 articles (03/2015 - 01/2004)|
01/01/2003 - "Urinary excretion of the marker of bone resorption (cross-linked N-telopeptide) was lower with SR than with placebo in the STRATOS study. "
04/01/1999 - "Urinary N telopeptide, a measure of bone resorption, also increased during the studies. "
01/01/1999 - "Throughout the study the marker of bone resorption, serum ICTP, was above normal, with a peak (mean values 67-69% above baseline) at 1 week (p = 0.0002) to 1 month (p < 0.0001). "
01/01/2016 - "Patients with increased PFV indices (above the median) exhibited lower CT density in the thoracic vertebrae (134±41 Hounsfield units vs. 161±57 Hounsfield units, p=0.04), and were more likely to have aortic valve calcification (48% vs. 18%, p=0.02) and N-telopeptide (bone resorption marker; 20.7±5.2nmolBCE/mmolCr vs. 25.5±5.9nmolBCE/mmolCr, p=0.03) levels than those without increased PFV indices. "
10/01/2015 - "In contrast, the amount of excreted urinary C-telopeptide, a bone resorption marker, increased transiently after single TPTD administration, and subsequently returned to control levels on the day after administration. "
|2.||Neoplasm Metastasis (Metastasis)
05/01/2003 - "Similarly the treatment of mice bearing bone metastasis with an MMP inhibitor led to a significant reduction of serum ICTP and CTX, and osteolytic lesions. "
01/01/2005 - "Serum ICTP level is more useful in staging metastasis. "
04/01/1999 - "Serum ICTP levels in patients with bone metastasis showed a significant downward trend in response to hormonal treatment. "
01/01/1999 - "Serum ICTP appears to be the leading marker of bone metastases from BC. "
08/01/1998 - "These results indicate that the measurement of serum ICTP concentration is useful for detecting and monitoring HCC patients with bone metastasis."
06/01/2003 - "ELISA was developed for detection of urinary N-telopeptide (NTx) as an osteoporosis marker. "
08/01/1997 - "Thus, serum ICTP is better than other peripheral markers in monitoring LT4 suppressive therapy in patients at increased risk for osteoporosis such as perimenopausal women."
06/11/2004 - "Serum levels of c-telopeptide, a marker of bone resorption, are increased in MCHR1(-/-) mice, indicating that the MCHR1(-/-) mice have a high bone turnover osteoporosis. "
06/01/2002 - "Our data suggest that N-telopeptide levels could be used as a tool for the screening of osteoporosis and for selecting those inflammatory bowel disease patients where bone mineral density measurement is indicated."
01/01/2013 - "We compared the measurements of urinary biochemical markers of bone turnover using cross-linked N-telopeptide (Ntx) values and BMD in 60 patients (49 females, 11 males; mean age: 65.7 years; range: 42 to 87 years) with osteoporosis who were treatment-naive and completed study. "
04/01/2000 - "These findings and the values of serum ICTP, PICP and BGP in pre- and postmenopausal women obtained in this study are expected to be very useful for treatment of postmenopausal osteoporosis."
01/01/2012 - "Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate."
01/01/1994 - "We conclude that serum ICTP does reflect bone metabolism in postmenopausal osteoporosis, but it is not a sensitive marker of the changes in bone resorption induced by hormone replacement therapy, and it does not correspond with other measures of bone resorption during anabolic steroid therapy."
12/01/2004 - "Using selected data from clinical studies involving 174 women with postmenopausal osteoporosis (PMO), a classical multicompartmental pharmacokinetic-pharmacodynamic (PK-PD) model was developed that accurately described the PK of i.v. ibandronate in plasma and urine and urinary excretion of the C-telopeptide of the alpha chain of type I collagen (uCTX), a sensitive biomarker of PD response to ibandronate. "
07/01/2003 - "In the Danish cohort (n = 306) of the Early Postmenopausal Intervention Cohort (EPIC) Study (n = 1609) of oral alendronate (ALN) for prevention of postmenopausal osteoporosis, bone markers (urine C-telopeptides of type I collagen (uCTX), urine N-telopeptide cross-links of type I collagen (uNTX), serum total osteocalcin measured by ELISA [total OC (ELISA)], and serum total osteocalcin measured by RIA [total OC (RIA)]) were measured at 6-month intervals. "
02/15/2002 - "In this study, pretreatment serum ICTP concentrations were measured by double-antibody radioimmunoassay in 50 patients undergoing tumor resection, chemoradiotherapy, or palliation for newly diagnosed esophageal SCC. "
11/01/2008 - "Mean +/- SD serum ICTP concentration in the tumor-bearing dogs was 7.32 +/- 2.88 ng/mL, and in clinically normal dogs, it was 6.77 +/- 2.31 ng/mL; values did not differ significantly. "
07/01/2005 - "In contrast, in animals having a high tumor burden of Neo cells, the serum levels of C-telopeptide and TRAP-5b never increase above the levels found before tumor injection. "
02/15/2002 - "Our results indicated that serum ICTP concentrations might be a novel prognostic tumor marker for assessing the progression of esophageal SCC."
08/01/2010 - "Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases."
|1.||collagen type I trimeric cross-linked peptide
|2.||Collagen Type I (Type I Collagen)
|6.||Biological Markers (Surrogate Marker)
|8.||Alendronate (Alendronate Sodium)
|1.||Drug Therapy (Chemotherapy)
|2.||Hormone Replacement Therapy (Therapy, Hormone Replacement)